Entero Therapeutics (NASDAQ:GRDX – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.
Entero Therapeutics Stock Performance
Shares of GRDX opened at $4.92 on Friday. The firm has a market cap of $35.08 million, a PE ratio of -2.59 and a beta of 1.66. The firm has a fifty day simple moving average of $4.11 and a two-hundred day simple moving average of $3.58. Entero Therapeutics has a 1-year low of $1.87 and a 1-year high of $6.93.
Entero Therapeutics Company Profile
Entero Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for gastrointestinal diseases. The company’s research programs are designed to address conditions involving intestinal inflammation, gluten intolerance and digestive enzyme deficiencies.
Its pipeline has included latiglutenase, an oral enzyme therapy being developed for celiac disease, as well as niclosamide-based therapies for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.
See Also
- Five stocks we like better than Entero Therapeutics
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
